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Summary 
The mouse mammary tumor virus-7 superantigen (vSAG7) is proteolytically processed in B cells 
at as many as three positions.  Proteolytic processing appears to be important  for superantigen 
activity because a processed form of vSAG7 was predominant among those forms that were found 
to bind  to major histocompatibility  complex class  II molecules.  To determine  the functional 
significance  of proteolytic processing,  a mutation was introduced in vSAG7 at one of the sites 
where proteolytic cleavage  is thought  to take place in B cells. Elimination  of the putative pro- 
cessing site at position 171 abrogated detectable vSAG7 surface expression in B cells, indicating 
that proteolytic processing is required for vSAG7 function. Coexpression in insect cells of vSAG7 
and furin,  a proprotein-processing enzyme, also demonstrated that furin could process vSAG7 
at position  171. 
S 
uperantigens  bind  to  MHC  class  II  molecules  and 
stimulate T  cells that bear specific VBs as part of their 
TCR (1, 2). They are encoded by bacteria and by mouse mam- 
mary tumor viruses (MMTVs). The soluble bacterial super- 
antigens have been well characterized at the biochemical and 
cellular levels, but the biochemical nature of the MMTV su- 
perantigens  (vSAGs) has been obscure. Biochemical studies 
of the superantigen encoded by MMTV7 (vSAG7) have indi- 
cated that vSAG7 is detected on the cell surface in a proteo- 
lytically processed form (3). Proteolytic processing is thought 
to occur in the Golgi region or in a post-Golgi compartment 
and yields a product(s) that is (are) cleaved at as many as three 
positions (4). At least one processed form of the protein has 
been shown to bind to MHC class II molecules (4).  It has 
not been determined,  however, if processing is required for 
normal vSAG7 function, and the exact positions in the pro- 
tein where the proteolytic processing occurs are unknown. 
vSAG7 is among a number of viral glycoproteins and cel- 
lular protein precursors that undergo proteolytic processing. 
Proteolytic cleavage of the precursor proteins commonly occurs 
at sites characterized by paired basic residues and is thought 
to result from the action of any of a family of mammalian 
subtilisin-like serine proteases (also known as proprotein con- 
vertases [PCs]) (5, 6). In several cases, proteolytic processing 
has been shown to be required for protein activity (7-10). 
Analysis of the vSAG7 amino acid sequence suggested the 
presence of three possible basic endoprotease recognition sites 
at residues 68-71 (RARR in single-letter amino acid code), 
168-171 (RKRR), and 190-194 (KEGKR). The approximate 
molecular weights of the vSAG7 proteolytic products that 
have been detected using SDS-PAGE are consistent with those 
predicted to be generated if cleavage occurred at or near these 
putative processing sites (4). Although a vSAG7 product, prob- 
ably processed at residues at 168-171, predominated among 
the forms found to be associated with  class  II I-A  k (4),  it 
has not been determined if proteolytic processing of vSAG7 
is required  for presentation  to T  cells. 
To determine the importance of residues 168-171 for pro- 
teolytic cleavage  and vSAG7 function,  amino acid substitu- 
tions were introduced at this position in vSAG7 using site- 
directed mutagenesis, and the effects of the substitutions on 
vSAG7 function were examined at the cellular and biochem- 
ical levels. In this study, we show that proteolytic cleavage 
was required for vSAG7 surface expression in B cells and pre- 
sentation to T cells. In addition, the furin endoprotease,  which 
recognizes the amino acid motif RXK/RR, is shown to be 
a candidate vSAG7-processing endoprotease. 
Materials and Methods 
Mutagenesis and Plasmids.  To generate each mutant sag7 gene, 
the sag7 gene was amplified by PCR with mutagenic primers, as 
shown in Fig. 1 B. For the sag7 mlyl mutation,  two different PCR 
products of the sag7 gene were amplified in separate reactions. One 
reaction used the 5' m171 primer  (5'-GAAAATGGAGAGGAG- 
TTCTCAACCGCA-Y)  and  primer  B  (5'-GGGGATCCCTAA- 
AAGGGATCGAAGCCGA-Y), and the other reaction used the 3' 
m171 primer (5'-TGCGGTTGAGAACTCCTCTCCATTTTC-Y) 
and primer A (5'-GGGAATTCTCGAGATGCCGCGCCTGCAG- 
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gether in the second round of the PCR, as described previously 
(11), with primers A and B, to generate the complete sag7  m171 gene 
(Fig. 1 B). The sag7  ~194 mutation was generated in a similar man- 
ner as sag7  m17~, except that different mutagenic primers were used: 
the 5' m194 primer (5'-AGAAGGAGAATTCAGTGTG-Y)  and the 
3' m194 primer (5'-CACACTGAATTCTCCTTCT-3'). The PCR 
products from each of the second reactions were cloned and se- 
quenced before any further manipulation. 
Constructs encoding soluble  forms of vSAG7 (BvSAG7) were 
generated by PCR using the primer (5'-GGGAATTCAAGATGG- 
CAATC GGTCTCCTGTGCTGTGCAGCCTTGTCTCTCCTG- 
TGGGCAGGTCCAGTGAATGCTGGTGTCACTCAGGGTG- 
GTGGTGTTGCGGTTCGTGCTCGCAGGGCT-3')  and primer B, 
described above, using the wild-type or mutant sag7 genes as tem- 
plates. The soluble forms lack the cytoplasmic domain and trans- 
membrane portion of vSAG7. The soluble forms were created by 
fusion  in  frame  to  the  human  TCK  V~813 signal  peptide 
(MAIGLLCCAALSLLWAGPVNA~GVTQ; 4  =  signal  peptide 
cleavage  site;  12).  After verifying the  sequences  of each  PCR. 
product, the genes encoding the soluble forms ofvSAG7 were cloned 
into a baculovirus expression vector pBACpl0pH (derived  from 
pAcUW51; PharMingen, San Diego, CA) (13) to generate the plas- 
mids pBsag7,  pBsag7  m171, and pBsag7  m194. The human furin (also 
known as PACE) cDNA was isolated from pMT3, kindly provided 
by Dr. A. RehemtuUa (Howard Hughes Medical Institute, Univer- 
sity of Michigan Medical Center, Ann Arbor, MI), and ligated into 
pBACpl0pH to create the plasmid pBAC-furin (14). 
Cell Culture, Transfections,  and Flow Cytometric Analysis.  The cul- 
ture of B cell lymphoma CH12.1 and the T cell hybridomas have 
been described previously (3, 11, 15). Spodopterafrugiperda (Sf9) cells 
were cultured in Grace's media (GIBCO BILL, Gaithersburg, MD) 
supplemented with 10% FCS, 100/.tg/ml penicillin  G, 200/zg/ml 
streptomycin, and 0.25/zg/ml amphotericin B. To generate B cell 
lines expressing vSAGs, the wild-type and sag7 m171 genes were in- 
serted into pH~SApr-l-neo  and transfected by electroporation into 
the B cell lymphoma CH12.1, as described previously (11). The 
transfectants were also examined for their ability to stimulate the 
T  cell hybridomas by measuring lymphokine production, as de- 
scribed  previously  (3).  Flow  cytometry  was  performed  on  a 
FACScan  |  (Becton Dickinson & Co., Mountain View, CA) flow 
cytometer, as described  previously (3, 4). 
Production of vSAG7  and Furin  in Insect Cells.  Recombinant 
baculoviruses  were produced by transfecting the transfer plasmids 
pBsag7, pBsag7  m171, pBsag7  mr94, and pBAC-furin with rescue viral 
DNAs into Sf9 cells using a transfection kit (BaculoGoldTM;  Phar- 
Mingen), following conditions as described by the manufacturer. 
For protein production, Sf9 cells were infected with cloned viruses 
and cultured for 3 d before preparing the supernatants or cell ly- 
sates. Furin enzyme activity from the membrane fractions was as- 
sayed as described previously (16, 17). 
Biochemical Characterization.  Cell  lysate  preparation,  affinity 
chromatography, endoglycosidase treatment, SDS-PAGE, and im- 
munoblotting  were  performed  as  described  previously  (3,  4). 
Purification of vSAG7 bound to class II I-A  k was performed as de- 
scribed  previously (4). 
Results  and  Discussion 
Proteolytic Processing Is Required  for vSAG7 Presentation.  The 
three putative processing sites in vSAG7 have been defined 
previously as the transmembrane (residues 68-71; RARR), 
proximal (168-171; RKRR),  and distal (190-194; KEGKR) 
A 
TM 
TTT T T  NIt21  ~  "[ COOH 
y  ,  ,A  y 
RARR  RKRR KR  VS1  VS7 
B 
~imer A 
f 
EcoR1 
I 
TM  vvv ￿9 ￿9 mutaggenic primers 
K\\\\\N 
mutagenie prhners  ~rhner  B 
PCR with primers A and B 
TM  vvv ￿9 ￿9  BamH1 
ligate into expression vector pH~APr-l-neo 
C 
~aI21 
TM 
I~l  vvv v v  COOH 
'A  t  I  ) 
RAP~  RKRR  KR  / 
M---PVNA~VTQGGGNSGEVAVRARR 
signal peptide cleavage site 
pBsag7 wt, m171, or m194 
Figure  1.  vSAG7  protein expression  vectors. (.4) Schematic of vSAG7 
illustrating the antibody binding sites (VS1, VST), the transmembrane 
region (TM), putative proteolytic  processing  sites (RARR, RKRR, KR), 
and the sites of N-linked glycosylation  (branches). (B) Mutant sag7 genes 
were generated using PCR, as shown and as described in Materials and 
Methods. Arrows, regions of primer-template hybridization; stippling, re- 
gion of hybridization of mutagenic oligonucleotides. (C) Strategy used 
for construction of baculovirus-vSAG7  expression vectors. A portion of 
the amino acid sequence  of the signal peptide and the position of the signal 
peptide cleavage site are shown. 
cleavage sites (5, 6) (Fig. 1 A). In particular, it has been sug- 
gested that proteolytic cleavage at the proximal site may be 
required for the binding of vSAG7 to MHC class II mole- 
cules (4). To directly test if proximal cleavage site-dependent 
processing was required for vSAG7 presentation to T  cells, 
amino acid substitutions were made at the proximal site by 
site-directed mutagenesis. The substitutions introduced acidic 
and hydrophobic residues in place of the tetrabasic sequence 
(RKRR to GEEF). The nonconservative substitutions were 
predicted to prevent processing by any of the known PCs (5, 6). 
The mutant sag7 gene, sag7 m171, was introduced into an 
expression vector under  the control of the human ~-actin 
promoter (Fig. 1 B) (18) and transfected into the B cell lym- 
phoma CH12.1 (15) to generate the cell line CH12.1/$7 m171. 
Surface expression  of the  wild-type  and  mutant  forms  of 
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Figure  2.  Mutant vSAG7s  are not detected  on the cell surface. The sur- 
face expression  of vSAG7 on cell lines, CH12.1, and the transfectants  was 
analyzed with VS7 antibody in the absence (dotted  line) or presence (solid 
line) of 1 mg/ml of the p7 competitor peptide as described  previously  (11). 
The levels of surface expression  of class II MHC proteins in the transfec- 
tants were not significantly different (data not shown). 
vSAG7 was analyzed by flow cytometry using the monoclonal 
antibody  VS7,  which  recognizes the  COOH  terminus  of 
vSAG7 (3). CH12.1/$7, the cell line transfected with the wild 
type sag7 gene, showed a significant level of vSAG7 surface 
expression, as previously reported (11).  In contrast,  no sur- 
face expression of vSAG7  was  observed on  CH12.1/$7 m171 
(Fig.  2). 
T  cell recognition is more sensitive than flow cytometry 
for assay of vSAG7 expression on B cells, so the transfectants 
were also tested for their ability to stimulate appropriate T 
cell hybridomas.  CH12.1/$7  stimulated T  cell hybridomas, 
which expressed the vSAG7-responsive V3 elements V36 and 
V/38.1, but these same hybridomas were not stimulated by 
CH12.1/$7 m171 (data not shown). The data suggest that the 
mutant  vSAG7 was  not transported  to the surface,  or was 
nonfunctional. The absence of detectable surface expression 
of vSAG7  mm  in  these  cells  was  probably  not  caused  by a 
failure in protein production because  a  significant  amount 
of intracellular protein was detected (Fig. 3). Therefore, pro- 
teolytic processing appeared to be critical for vSAG7 presen- 
tation  to  T  cells  and/or  for proper  surface expression. 
To determine if the vSAG7  mitt underwent any proteolytic 
processing,  the protein was  partially purified and  analyzed 
biochemically. In experiments using CH12.1/$7, VS7 detected 
several  forms  of  vSAG7,  including  a  precursor  protein 
(gpPr45m),  and two  COOH-terminal  proteolytic cleavage 
products,  previously defined as p18 and p16 (Fig.  3)  (4).  It 
was  suggested  that  p18  and  p16  originated  as  a  result  of 
proteolytic  processing  at  the  proximal  and  distal  vSAG7 
cleavage sites,  respectively.  In  af~nity-purified preparations 
of vSAG7  m171, gpPr45m  was  detected,  but  only  a  single 
COOH-terminal  cleavage product  was  apparent  (Fig.  3  a, 
lane 2). Comparison of the vSAG  m171 with wild-type vSAG7 
revealed that  the cleavage product  detected in preparations 
of  CH12.1/$7 mitt  protein  corresponded  to  the  cleavage 
product p16, indicating that the m171 substitution eliminated 
the production of p18 in B  cells  (Fig.  3  b,  lanes  1  and 2). 
Therefore, p18 in vSAG7 originated most likely after proteo- 
lytic processing at the proximal cleavage site, as has been pre- 
viously suggested  (4). 
It has been demonstrated previously that p18, but not p16, 
binds  to the dass  II molecule I-A  k (4).  To further support 
the  conclusion  that  the  vSAG7  m171  proteolytic  cleavage 
product  was  indeed  p16,  the  migration  of vSAG7  m171 was 
compared with vSAG7 products that were found to bind to 
I-A  k (Fig.  3  b).  The data in Fig.  3  b demonstrate  that  the 
vSAG7  mitt cleavage  product  does  not  comigrate  with  the 
vSAG7  cleavage product,  p18,  that  was  found  to  bind  to 
I-A  k. 
The Transmembrane and Proximal Proteolytic Processing Sites 
Are Substrates for the Endoprotease Furin.  The basic  amino 
acid  proteolytic cleavage sites  that  have been  described  in 
Figure 3.  The m171 substitution  eliminated pro- 
teolytic processing at  the proximal cleavage site. (a) 
vSAG7  m171 was  purified by affinity chromatography, 
treated with N-glycanase (+), or left untreated (-), as 
indicated, electrophoresed  in a 8-20% SDS-polyacryl- 
amide gradient gel, transferred  to blotting membranes, 
and detected with VS7 in the presence (+) or absence 
(-) of the p7 competitor  peptide, gPr45 is the full-length 
high mannose (endo H-sensitive) form of the vSAG7 
(4). *The COOH-terminal  vSAG7  m171 cleavage  prod- 
uct. Ig, immunoglobulin light chain eluted from the 
a~nity column and detected  by the secondary  antibodies. 
(b) Cell lysates from CH12.1/$7 (wt) or CH12.1/$7 m171 
(m  171 ) were chromatographed  on af~nity  columns  con- 
taining antibodies directed  against vSAG7 (VS1) or I-A  k 
(17/227) as described  previously  (4). The column eluates 
were examined  by Western analysis  using VST. The po- 
sitions of the wild type proteolytic cleavage  products 
(p18 and p16) are indicated. Molecular mass markers, 
in kilodahons, are indicated at the left of each gel. 
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been detected in most mammalian cell types, including thymus 
and spleen (19,  20), unlike other PCs, which are expressed 
primarily in neuroendocrine  tissues (21,  22). Therefore, ex- 
periments were performed to determine if furin could act as 
a vSAG7-processing endoprotease. 
A  soluble form of vSAG7 (BvSAG7) was engineered by 
truncation of the cytoplasmic and transmembrane regions and 
by introduction  of a  signal  peptide  to  facilitate  secretion. 
BvSAG7 was expressed in Sf9 cells after infection with recom- 
binant baculoviruses containing  the Bsag7 gene (Fig.  1 C). 
BvSAG7 was detected in the culture medium by Western anal- 
ysis using the VS7 antibody. BvSAG7 was secreted from Sf9 
cells in three forms: an N-glycosylated major product of 36 
kD (gp36), a minor N-glycosylated product of 33 kD (gp33), 
and a nonglycosylated proteolytic product, p18 (Fig. 4, lanes 
1 and 5).  The N-glycosylation status of the products were 
determined  using N-glycanase  (data  not  shown). 
Similar results were obtained in parallel experiments using 
recombinant baculoviruses that expressed a form of BvSAG7 
that contained a peptide epitope at the NH2 terminus of the 
secreted protein.  The peptide allowed BvSAG7 to be recog- 
nized by the mAb  12CA5  (23).  Among the three secreted 
protein  products  recognized  with  VS7  antibody,  only the 
major protein product, gp36, was also recognized by 12CA5 
antibody (Park,  C.  G.,  M.  Y. Jung,  and  Y.  Choi,  unpub- 
lished data). These data indicated  that the major product (gp36) 
was the full-length BvSAG7 protein and the other proteins 
were proteolytic processing products. 
The p18 secreted by the Sf9 cells was similar in size to the 
COOH-terminal  cleavage product of vSAG7 detected in B 
Figure 4.  Baculovirus  expression  of vSAG7  and proteolytic  cleavage  by 
the endoprotease  furin. (Left)  Culture supernatants from Sf9 cells  that had 
been infected  with recombinant baculoviruses  carrying Bsag7  or Bsag7m171 
were incubated  with membrane preparations obtained  from either control 
baculovirus-infected  Sf9 cells (-) or from Sf9 cells infected  with viruses 
carrying the mammalian furin gene (+). The supernatants were electro- 
phoresed  in a 8-20% SDS-polyacrylamide  gradient gel, transferred to blot- 
ting membranes, and detected using VS7. (Right)  Sf9 cells were infected 
with baculoviruses  expressing  the wild-type  or mutant BvSAG7  alone (-) 
or coinfected  with baculoviruses  carrying the mammalian furin gene (+). 
Culture supernatants were electrophoresed  in a 10-20% SDS-polyacryl- 
amide gradient gel, and vSAG7  proteins  were detected  by Western analysis 
using VS7. gp36, full length BvSAGT;  gp33, BvSAG7  proteolytic  cleavage 
product generated  by processing  at the putative transmembrane processing 
site; p18, BvSAG7  product generated by processing  at the proximal site. 
The relative amounts of three protein products, gp36, gp33, and p18, were 
quantified with the enhanced laser densitometer (Uhrascan XL; LKB In- 
struments, Bromma, Sweden)  and described  in the Materials and Methods. 
cells,  and gp33 was hypothesized to originate from proteo- 
lytic cleavage at the RARR sequence found at residues 15-18 
of the recombinant  protein,  BvSAG7 (Fig.  1 C).  The data 
suggested that Sf9 cells contain an endogenous furinlike ac- 
tivity, as has been suggested (24), and that BvSAG7 protein 
can undergo  limited  proteolytic processing in  insect  cells. 
BvSAG7 was also treated  with  membrane  fractions pre- 
pared from Sf9 cells expressing the human furin gene. Under 
these conditions, the amount of the proteolytic cleavage prod- 
ucts p18 and gp33 increased to two- to threefold relative to 
the full-length gp36 protein (Fig. 4). Similar results were ob- 
tained when BvSAG7 was coexpressed with furin in Sf9 cells 
(Fig.  4, lanes 5-8).  Therefore,  BvSAG7 was a substrate for 
furin. The enhanced production ofgp33 upon treatment with 
the furin-containing membrane fractions also suggested that 
the putative transmembrane cleavage site (RARR) was a sub- 
strate for the furin  endoprotease. 
To identify the COOH-terminal  cleavage  site recognized 
by human  furin,  soluble forms of vSAG7  m171 (BvSAG7  m171) 
and  a  second  mutant  protein,  BvSAG7  m194, were also  ex- 
pressed  in  Sf9  cells.  BvSAG7  ~19a contains  substitutions  at 
residues  193-194  (KR changed  to EF)  that  were predicted 
to eliminate  the distal  putative  proteolytic processing site. 
Because the distal processing site did not appear to be recog- 
nized by furin in insect cells, it was not possible to examine 
the effect of the amino  acid substitutions  on processing at 
this site. However, BvSAG7  m194 migrated in a manner similar 
to BvSAG7, and coexpression with  furin  greatly enhanced 
production of the COOH-terminal cleavage product p18 (Fig. 
4,  lanes  7 and 8).  In contrast,  p18 was not  generated  as a 
proteolytic  cleavage  product  of BvSAG7  m171, either  in  the 
presence or absence of furin (Fig.  4, lanes 3 and 4 and lanes 
9  and  10). 
These data suggested that in Sf9 cells, p18 was generated 
by proteolytic processing at the proximal cleavage site (RKRR) 
of vSAG7, as in B cells, and this site was a substrate for furin. 
These results  are  consistent  with  the earlier  interpretation 
that vSAG processing occurs in the Golgi region or a post- 
Golgi compartment  (4), where furin has been shown to be 
localized (25). Furthermore,  the results also indicate that the 
putative distal processing site was not a substrate for furin. 
This suggests that a processing enzyme other than furin may 
generate the COOH-terminal cleavage product p16, that the 
distal site is not accessible to furin in BvSAG7, or that  the 
specificity of furin may differ between insect and B cells. The 
analyses have not localized the precise site of the distal cleavage 
event used to generate  p16. 
The data presented here show that proteolytic processing 
is required for T  cell stimulation  and/or  surface  expression 
of vSAG7 in B cells. Because full-length vSAG7 has not been 
unambiguously  detected on  the cell  surface of an APC,  it 
is unknown if vSAG7 will activate T  cells in the absence of 
proteolytic processing. Nevertheless, the data presented here 
demonstrate  that  proteolytic processing is a requisite event 
for viral  superantigen  presentation  by APC. 
Earlier work suggested that proteolytic processing at the 
proximal endoprotease site may enhance binding of vSAG7 
to  class  II  MHC  (4).  vSAG7  m171 was  not  proteolytically 
1902  Proteolytic  Processing of Viral Superantigen processed to p18, so presumably it does not bind,  or binds 
weakly to class II.  Therefore, one possible explanation for 
the failure to observe surface expression of vSAG7  m171 is that 
class II binding is a prerequisite for efficient surface expres- 
sion of vSAG in B  cells,  as has been  suggested  (3). 
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